Fidson selected as regional sublicensee to expand access to influenza treatment and strengthen pandemic preparedness

AI Summary

Nigeria’s Fidson Healthcare has been selected as a regional sublicensee to develop and manufacture generic baloxavir marboxil, a treatment for influenza. The voluntary licence, coordinated through the Medicines Patent Pool and Roche, includes manufacturers in multiple countries and aims to broaden access and strengthen pandemic preparedness.

Fidson joins manufacturers across Brazil, China, India, Indonesia, Malaysia, Uganda, Ukraine and Vietnam under sublicence agreements to develop and manufacture generic versions of Roche’s baloxavir marboxil through MPP’s voluntary licence, supporting diversified manufacturing capacity and stronger pandemic preparedness. The leading pharmaceutical manufacturing company in Nigeria, Fidson Healthcare Plc has been selected as one of eleven […] The post Fidson selected as regional sublicensee to expand access to influenza treatment and strengthen pandemic preparedness appeared first on Nairametrics.